SecBot SecBot
SECBOTREPLAY Home › Report › IMTX

IMTX · Immatics reported Q1 2026 financial results showing a net loss of €57.8…

Immatics N.V. · 6-K filed May 12, 2026 at 07:08 ET

At the news

BEARISHIMPACT 6/10

6-K filed May 12, 2026 at 07:08 ET

Immatics reported Q1 2026 financial results showing a net loss of €57.8 million ($66.5 million) on revenue of €7.6 million ($8.7 million), compared to a net loss of €39.9 million on revenue of €18.6 million in Q1 2025. Revenue declined 59% YoY due to lower cost recognition on collaboration agreements, while R&D expenses surged 41% to €59.2 million driven by the SUPRAME Phase 3 trial. Cash and equivalents plus other financial assets stood at €453.6 million ($521.5 million), with cash runway projected into 2028. The company reiterated key 2026 catalysts including SUPRAME interim/final analysis triggers and multiple ASCO data presentations, but the widening operating loss and revenue decline overshadow pipeline progress.

  • Net loss widened to €57.8 million in Q1 2026 from €39.9 million in Q1 2025, a 45% increase
  • Revenue from collaboration agreements fell 59% to €7.6 million from €18.6 million YoY
  • R&D expenses increased 41% to €59.2 million, primarily from SUPRAME Phase 3 trial costs
  • Operating loss deepened to €66.1 million from €35.4 million YoY

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access